(secondQuint)LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease.

 This study is organized into 2 phases.

 Following a 2-week identification phase, eligible subjects with severe dry eye disease (DED) will be randomized into the treatment phase and will be dispensed study treatment for 10 weeks.

.

 LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease@highlight

The purpose of this study is to evaluate the efficacy of LME636 compared to vehicle in the reduction of ocular symptoms and to evaluate the safety and tolerability of LME636, when administered topically for up to 42 days, in subjects with severe dry eye disease.

